Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS3 | P17931 | 5/20 | 0.51 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.51 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.51 |
| ▸ | LGALS1 | P09382 | 1/20 | 0.47 |
| ▸ | LGALS7; LGALS7B | P47929 | 1/20 | 0.47 |
| ▸ | STAT3 | P40763 | 4/20 | 0.47 |
| ▸ | CD69 | Q07108 | 1/20 | 0.46 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.46 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | SELE | P16581 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15258381 | 0.96 | LGALS3 (0.48) | LGALS3LGALS8LGALS4LGALS1LGALS7; LGALS7B | |
| SCHEMBL25787341 | 0.96 | LGALS3 (0.52) | LGALS3LGALS8LGALS4LGALS1LGALS7; LGALS7B | |
| SCHEMBL16407356 | 0.96 | LGALS3 (0.52) | LGALS3LGALS8LGALS4LGALS1LGALS7; LGALS7B | |
| SCHEMBL21678048 | 0.96 | LGALS3 (0.52) | LGALS3LGALS8LGALS4LGALS1LGALS7; LGALS7B | |
| SCHEMBL24495336 | 0.96 | LGALS3 (0.52) | LGALS3LGALS8LGALS4LGALS1LGALS7; LGALS7B | |
| SCHEMBL23057244 | 0.96 | LGALS3 (0.52) | LGALS3LGALS8LGALS4LGALS1LGALS7; LGALS7B | |
| SCHEMBL19453261 | 0.94 | LGALS3 (0.48) | LGALS3LGALS8LGALS4LGALS1LGALS7; LGALS7B | |
| SCHEMBL25787418 | 0.94 | LGALS3 (0.59) | LGALS3LGALS8LGALS4LGALS1LGALS7; LGALS7B | |
| SCHEMBL25787342 | 0.94 | LGALS3 (0.59) | LGALS3LGALS8LGALS4LGALS1LGALS7; LGALS7B | |
| SCHEMBL18645639 | 0.93 | LGALS3 (0.52) | LGALS3LGALS8LGALS4LGALS1LGALS7; LGALS7B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3569230-A1 | REDUCTION OF GASTROINTESTINAL TRACT COLONISATION BY CAMPYLOBACTER | Akeso Biomedical, Inc. (US) | 2019-11-20 | — | — | EP | disclosed |
| US-20190314323-A1 | REDUCTION OF GASTROINTESTINAL TRACT COLONISATION BY CAMPYLOBACTER | Akeso Biomedical, Inc. | 2019-10-17 | — | — | US | disclosed |
| US-20190083447-A1 | REDUCTION OF GASTROINTESTINAL TRACT COLONISATION BY CAMPYLOBACTER | Akeso Biomedical, Inc. | 2019-03-21 | — | — | US | disclosed |
| US-10195172-B2 | Reduction of gastrointestinal tract colonisation by Campylobacter | Akeso Biomedical, Inc. (US) | 2019-02-05 | — | — | US | disclosed |
| US-20170231945-A1 | REDUCTION OF GASTROINTESTINAL TRACT COLONISATION BY CAMPYLOBACTER | Akeso Biomedical, Inc. | 2017-08-17 | — | — | US | disclosed |
| US-20170231945-A1 | REDUCTION OF GASTROINTESTINAL TRACT COLONISATION BY CAMPYLOBACTER | Akeso Biomedical, Inc. | 2017-08-17 | — | — | US | disclosed |
| US-9655912-B2 | Reduction of gastrointestinal tract colonisation by campylobacter | Akeso Biomedical, Inc. (US) | 2017-05-23 | — | — | US | disclosed |
| US-9655912-B2 | Reduction of gastrointestinal tract colonisation by campylobacter | Akeso Biomedical, Inc. (US) | 2017-05-23 | — | — | US | disclosed |
| US-20150025026-A1 | REDUCTION OF GASTROINTESTINAL TRACT COLONISATION BY CAMPYLOBACTER | MAHDAVI, JAFAR (GB) | 2015-01-22 | — | — | US | disclosed |
| WO-2013121214-A1 | REDUCTION OF GASTROINTESTINAL TRACT COLONISATION BY CAMPYLOBACTER | THE UNIVERSITY OF NOTTINGHAM (GB) | 2013-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10195172-B2 | Reduction of gastrointestinal tract colonisation by Campylobacter | FABP2, MLN, SLC10A2 | LGALS3 522/4885LGALS8 971/4885LGALS4 502/4885 |
| US-20150025026-A1 | REDUCTION OF GASTROINTESTINAL TRACT COLONISATION BY CAMPYLOBACTER | FABP2, MLN, MLNR | LGALS3 673/4885LGALS8 1133/4885LGALS4 532/4885 |
| US-20190083447-A1 | REDUCTION OF GASTROINTESTINAL TRACT COLONISATION BY CAMPYLOBACTER | FABP2, MLN, MLNR | LGALS3 673/4885LGALS8 1133/4885LGALS4 532/4885 |
| US-20190314323-A1 | REDUCTION OF GASTROINTESTINAL TRACT COLONISATION BY CAMPYLOBACTER | FABP2, MLN, MLNR | LGALS3 623/4885LGALS8 1027/4885LGALS4 574/4885 |
| US-20170231945-A1 | REDUCTION OF GASTROINTESTINAL TRACT COLONISATION BY CAMPYLOBACTER | FABP2, MLN, MLNR | LGALS3 673/4885LGALS8 1133/4885LGALS4 532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.